Keywords: supergen, update, nipent, firm, said, due, lower-than-

SuperGen update on Nipent

Article | 05 January 2004

Print This

US firm SuperGen has said that, due to lower-than- expected demand forNipent (pentostatin for injection) during the fourth quarter, total ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in